Determining whether Armata Pharmaceuticals represents a favorable investment depends heavily on an investor's risk tolerance regarding clinical-stage biotechnology enterprises. The company specializes in developing innovative synthetic bacteriophage therapeutics designed to treat severe antibiotic-resistant bacterial infections, offering high potential upside if its clinical trials succeed and regulatory approvals are secured. However, like many pre-revenue biotech firms, it carries substantial clinical trial risks, relies heavily on periodic capital raises, and experiences significant share price volatility, making it suitable primarily for speculative growth portfolios.